|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1996
|
|
gptkbp:atccode
|
N06 DA02
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:brand
|
gptkb:Aricept
|
|
gptkbp:casnumber
|
120014-06-4
|
|
gptkbp:chemical_formula
|
C24 H29 NO3
|
|
gptkbp:class
|
acetylcholinesterase inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to donepezil
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
long-term use
|
|
gptkbp:effect_on_behavior
|
reduces behavioral symptoms
|
|
gptkbp:effect_on_cognition
|
improves cognitive function
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
donepezil hydrochloride
|
|
gptkbp:indication
|
mild to moderate dementia
|
|
gptkbp:interacts_with
|
NSAIDs
antidepressants
beta-blockers
anticholinergic drugs
|
|
gptkbp:is_monitored_by
|
monitor for side effects
regular cognitive assessments
|
|
gptkbp:lifespan
|
70 hours
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
gptkb:Eisai
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
many countries
|
|
gptkbp:mechanism_of_action
|
inhibits acetylcholinesterase
|
|
gptkbp:metabolism
|
gptkb:CYP2_D6
gptkb:CYP3_A4
|
|
gptkbp:provides_guidance_on
|
recommended for Alzheimer's treatment
|
|
gptkbp:requires
|
available online
|
|
gptkbp:research_focus
|
combination therapies
new formulations
patient adherence studies
long-term efficacy studies
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
insomnia
muscle cramps
|
|
gptkbp:storage
|
room temperature
keep out of reach of children
protected from moisture
|
|
gptkbp:symptoms
|
none reported
|
|
gptkbp:treatment
|
improve quality of life
slow disease progression
enhance daily functioning
|
|
gptkbp:used_for
|
gptkb:neurodegenerative_diseases
|
|
gptkbp:bfsParent
|
gptkb:Aricept
|
|
gptkbp:bfsLayer
|
6
|